RED:NICE TA1036: Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment
Red Drug Classifications
8. NHS England commissioned – to be used in line with NHSE commissioning intentions
